相似文献
1
Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
J Infect Dis. 2022 Feb 15;225(4):598-602. doi: 10.1093/infdis/jiab570.
2
Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
Vaccine. 2023 Aug 7;41(35):5195-5200. doi: 10.1016/j.vaccine.2023.07.011. Epub 2023 Jul 13.
3
Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
J Clin Virol. 2021 Dec;145:105026. doi: 10.1016/j.jcv.2021.105026. Epub 2021 Nov 8.
4
Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.
Transpl Infect Dis. 2022 Apr;24(2):e13779. doi: 10.1111/tid.13779. Epub 2022 Jan 31.
5
SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176. doi: 10.15585/mmwr.mm7034e5.
6
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
J Infect Dis. 2021 Oct 28;224(8):1278-1286. doi: 10.1093/infdis/jiab377.
7
The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.
Transpl Immunol. 2023 Apr;77:101777. doi: 10.1016/j.trim.2022.101777. Epub 2022 Dec 28.
8
Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Chest. 2023 May;163(5):1061-1070. doi: 10.1016/j.chest.2022.10.020. Epub 2022 Oct 28.
9
Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19.
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211019282. doi: 10.1177/21501327211019282.
10
Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination.
Int J Infect Dis. 2021 Sep;110:353-358. doi: 10.1016/j.ijid.2021.08.008. Epub 2021 Aug 8.
引用本文的文献
1
Severe outcomes of COVID-19 among adults with increased risk conditions: A population-based observational study.
PLoS One. 2025 Feb 11;20(2):e0316529. doi: 10.1371/journal.pone.0316529. eCollection 2025.
2
Using a web platform for equitable distribution of COVID-19 monoclonal antibodies: a case study in resource allocation.
Front Public Health. 2023 Nov 28;11:1226935. doi: 10.3389/fpubh.2023.1226935. eCollection 2023.
3
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2.
Viruses. 2023 Jun 27;15(7):1449. doi: 10.3390/v15071449.
4
Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center.
Med J Armed Forces India. 2023 May 18;80(Suppl 1):S180-4. doi: 10.1016/j.mjafi.2023.03.006.
5
19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern.
iScience. 2023 Apr 21;26(4):106562. doi: 10.1016/j.isci.2023.106562. Epub 2023 Apr 1.
6
Retrospective Analysis of Vaccinated and Unvaccinated COVID-19 Patients Treated with Monoclonal Antibodies (mAb) and Their Emergent Needs (RAVEN).
Vaccines (Basel). 2023 Mar 17;11(3):688. doi: 10.3390/vaccines11030688.
7
Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort.
J Clin Med. 2023 Jan 21;12(3):864. doi: 10.3390/jcm12030864.
8
Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series.
Viruses. 2022 Dec 30;15(1):102. doi: 10.3390/v15010102.
9
Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score.
Mayo Clin Proc Innov Qual Outcomes. 2023 Apr;7(2):109-121. doi: 10.1016/j.mayocpiqo.2022.12.007. Epub 2023 Jan 11.
10
Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database.
BMJ Open. 2022 Dec 19;12(12):e064953. doi: 10.1136/bmjopen-2022-064953.
Zotero 插件